The prescription drug benefit arm of CVS said Monday that it will exclusively cover two costly hepatitis C drugs that were until recently the only oral treatments available for the disease, following moves by a competitor to cover an alternative drug.

Hepatitis C treatment has gone from a miserable process of daily injections to simple daily pills in recent years. But the cost of these new pills are exorbitant. One of the first companies to hit the mark with oral treatments, Gilead Sciences, offers two drugs for hepatitis C: Harvoni costs $95,500 for 12 weeks, and Sovaldi, costs $84,000. That’s $1,000 per pill.

But as TIME reported last month, the U.S. Food and Drug Administration (FDA) approved a new hepatitis C drug called Viekira Pak, developed by the pharmaceutical company AbbVie. At $83,319 for a 12-week course it’s only slightly less than what Gilead offers. The hope had been that more competition would drive down prices. In an effort to do just that, pharmacy benefit manager—and CVS competitor—Express Scripts negotiated a discount for Viekira Pak in exchange for making the drug the exclusive offering for its 25 million customers.

MORE: Why Hepatitis C Drugs May Soon Get Far Less Expensive

Now CVS has made a similar deal with Gilead Sciences, CNBC reports. It will offer the companies’ drugs exclusively for it’s customers, though it’s unclear whether the drugs will indeed be discounted.

“Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of hepatitis C,” said CVS Health spokesperson Chris Cramer. “When making this decision, we evaluated a wide variety of factors including duration of therapy, relative distribution of genotype and cost of the individual agents in the category as well as the results of a comprehensive clinical review of the different hepatitis C regimens.”

Get our Health Newsletter. Sign up to receive the latest health and science news, plus answers to wellness questions and expert tips. Please enter a valid email address. Sign Up Now Check the box if you do not wish to receive promotional offers via email from TIME. You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Thank you! For your security, we've sent a confirmation email to the address you entered. Click the link to confirm your subscription and begin receiving our newsletters. If you don't get the confirmation within 10 minutes, please check your spam folder.

Contact us at letters@time.com.